**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Gina Barzen, MD,  Deutsches Herzzentrum der Charité – Department of Cardiology, Angiology and Intensive Care Medicine, Charitéplatz 1, 10117 Berlin, Germany

**Main Body of the Abstract**
Introduction Patients with restrictive cardiomyopathy(CM) due to wtATTR unfortunatly often respond poorly to standard heart failure medications.To date, there is limited data on SGLT-2 inhibitors in patients with cardiac amyloidosis. The aim of this study is to investigate the tolerability and efficacy of the SGLT-2 inhibitors empagliflozin and dapagliflozin in patients with cardiac amyloidosis.
Methods Patients from our amyloidosis center with wtATTR-CM who were already treated with tafamidis 61 mg once daily were prescribed empagliflozin or dapagliflozin. Patients were assessed for NYHA class LVEF, global strain, NTpro- BNP as well as renal function and HbA1c at time of prescription as well as 3-6 month after.
Results We included 19 patients (17 men) with an average age of 80 years. 5 patients were treated with dapagliflozin and 14 with empagliflozin. None of the patients reported a drug-related genitourinary infection. Mean left ventricular ejection fraction (LVEF) was 51% at baseline (SD 8,1) and remained stable after 3-6 months (mean 51%, SD 6,3). There were no significant changes in LVEF, global strain , NYHA stage, NTproBNP , creatinine or GFR levels and HbA1c.
Conclusion Some patients with amyloidosis respond particularly well to SGLT2 inhibitor therapy. However, due to the small number of patients, we have not yet been able to detect any significant changes. Still it is important to emphasize that no relevant drug-associated adverse events occurred in our cohort. Further studies are needed to investigate the effect of SLGT2 inhibitors in patients with cardiac amyloidosis in more detail.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Gina Barzen, MD,  Deutsches Herzzentrum der Charité – Department of Cardiology, Angiology and Intensive Care Medicine, Charitéplatz 1, 10117 Berlin, Germany

**Main Body of the Abstract**
**Introduction** Patients with restrictive cardiomyopathy(CM) due to wtATTR unfortunatly often respond poorly to standard heart failure medications.To date, there is limited data on SGLT-2 inhibitors in patients with cardiac amyloidosis. The aim of this study is to investigate the tolerability and efficacy of the SGLT-2 inhibitors empagliflozin and dapagliflozin in patients with cardiac amyloidosis.
**Methods** Patients from our amyloidosis center with wtATTR-CM who were already treated with tafamidis 61 mg once daily were prescribed empagliflozin or dapagliflozin. Patients were assessed for NYHA class LVEF, global strain, NTpro- BNP as well as renal function and HbA1c at time of prescription as well as 3-6 month after.
**Results** We included 19 patients (17 men) with an average age of 80 years. 5 patients were treated with dapagliflozin and 14 with empagliflozin. None of the patients reported a drug-related genitourinary infection. Mean left ventricular ejection fraction (LVEF) was 51% at baseline (SD 8,1) and remained stable after 3-6 months (mean 51%, SD 6,3). There were no significant changes in LVEF, global strain , NYHA stage, NTproBNP , creatinine or GFR levels and HbA1c.
**Conclusion** Some patients with amyloidosis respond particularly well to SGLT2 inhibitor therapy. However, due to the small number of patients, we have not yet been able to detect any significant changes. Still it is important to emphasize that no relevant drug-associated adverse events occurred in our cohort. Further studies are needed to investigate the effect of SLGT2 inhibitors in patients with cardiac amyloidosis in more detail.



SGLT-2- inhibitors in patients with cardiac wildtype ATTR- amyloidosis PC96 (#41)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.